See inside every stock. Pro
S&P 5007,663▼ 1.21%Nasdaq26,009▼ 2.60%Dow Jones52,868▲ 0.02%Nasdaq 10028,959▼ 2.90%VIX19.03▲ 14.09%US Dollar101.62▼ 0.16%Gold spot4,093▼ 0.80%WTI100.69▲ 1.23%
← DXRX page
XStocksXray
Market X-Ray report · 22 October 2026

Diaceutics PLC (DXRX)

London Exchange · UK · prices in GBX · close of 22 Oct 2026

Key indicators

Last closeGBX 199.00
52-week range125.00 – 210.00
Return, 1 month / 3 months+7.0% / +50.8%
Return, 1 year / 3 years+24.0% / +116.3%
TrendUptrend
RSI (14)66
Volatility (1 year)33.6%
Worst drawdown (1 year)-28.3%
Average daily value traded50.03M GBX
Dividend yield–

Market X-Ray price-based

75/ 100 · High confidence · ahead of 93% of stocks on this exchange
Trend86
Momentum79
Stability (higher is calmer)52
Liquidity85
Income–

Five-year price chart navy: price · brown: 200-day average

66.701031401762122021-102023-032024-062025-082026-10

About the company

Diaceutics is a healthcare data and advisory company based in Belfast that works with pharmaceutical and diagnostic firms on precision medicine. It gathers and analyses testing and diagnostic data, then advises drug makers on how to connect their treatments with the patients most likely to benefit. Its services support the development and commercialisation of companion diagnostics, which pair a medicine with a test that identifies suitable patients.

On this site Diaceutics PLC appears as a stock on the London Exchange (UK), code DXRX, with prices in pence sterling (GBX). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.

Summary

Diaceutics PLC (DXRX) trades on the London Exchange in UK. It last closed at GBX 199.00 on 22 October 2026.

Its price-based Market X-Ray is 75 out of 100 (a strong price profile), ranking 275 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.

Over the last year the price rose 24.0% and over the last three months it rose 50.8%. Returns are price returns, dividends not included.

Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.

stocksxray.com · page 1
XStocksXray
Diaceutics PLC (DXRX)

The five lenses in numbers each metric is ranked against the other stocks on London Exchange

Lens and metricValueScoreReading
Trend86 · StrongTrading above its long-term averages and near its highs.
Above 200-day average26.1%
From 52-week high-2.7%
Momentum79 · StrongRising faster than most stocks on this exchange.
3-month return50.8%
6-month return14.4%
12-month return, skipping the last month15.9%
Stability (higher is calmer)52 · FairTypical risk for this exchange.
Volatility, 1 year (lower is calmer)33.6%
Worst drawdown, 1 year (smaller is calmer)-28.3%
Liquidity85 · StrongTrades actively.
Average daily value traded50.03M GBX
Zero-volume days0.0%
Income–Pays no dividend.
Dividend yield–
Years with dividends0

Strengths

  • Trend: Trading above its long-term averages and near its highs.
  • Momentum: Rising faster than most stocks on this exchange.
  • Liquidity: Trades actively.

Weak spots

No lens is weak against its exchange.

Returns

1 week−1.7%
1 month+7.0%
3 months+50.8%
6 months+14.4%
1 year+24.0%
3 years+116.3%
5 years+80.1%

Signals

50-day / 200-day average171.76 / 157.81
Golden / death cross (60 days)Golden, 15 days ago
New 52-week highNo
Bullish RSI divergenceNo
Average daily range (ATR)5.87

Technical summary

DailyBullish9 bullish · 4 neutral · 3 bearish
WeeklyStrongly bullish11 bullish · 1 neutral · 0 bearish
MonthlyStrongly bullish7 bullish · 1 neutral · 0 bearish

How to read this report

Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.

stocksxray.com · page 2 · generated 23 Oct 2026